Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytarabine/daunorubicin - CSPC Pharmaceutical Group

Next Previous
X
Search
Drug Profile

Cytarabine/daunorubicin - CSPC Pharmaceutical Group

Alternative Names: Cytarabine: daunorubicin liposome for injection; Daunorubicin cytarabine liposome for injection; Daunorubicin/cytarabine - CSPC Pharmaceutical Group

Latest Information Update: 06 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Pharmaceutical Group
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; DNA-directed DNA polymerase inhibitors; DNA-directed RNA polymerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute myeloid leukaemia

Most Recent Events

  • 01 Jan 2024 CSPC Zhongnuo Pharmaceutical plans a phase III trial for Acute myeloid leukemia (First line therapy, In elderly, In adults) in China (IV, Infusion) (NCT06182592)
  • 25 Aug 2023 Clinical trials in Acute myeloid leukaemia (In the elderly) in China (IV) (NCT05801835)
  • 27 Jul 2023 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top